In addition, as CD4 is known to have anti-tumor activity in melanoma [34], observing a significantly lower proportion of CD4 T cells in males stage III could possibly explain the significantly worse overall survival observed in this group compared to stage I, II females and males, as well as the worse overall survival trend compared to stage III females. The gene discussed is CD4; the disease is melanoma.